Cigna Group (CI) FinancialsCICigna Group

The Cigna Group (CI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pharmacy revenues, accounting for 79.8% of total sales, equivalent to $57.17B. Other significant revenue streams include Premiums and Fees and other revenues. Understanding this composition is critical for investors evaluating how CI navigates market cycles within the Managed Healthcare industry.

Evaluating the bottom line, The Cigna Group maintains a gross margin of 8.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 3.99%, while the net margin is 2.62%. These profitability ratios, combined with a Return on Equity (ROE) of 15.49%, provide a clear picture of how effectively CI converts its operational activities into shareholder value.

In the context of the broader market, CI competes directly with industry leaders such as ELV and HUM. With a market capitalization of $74.66B, it holds a significant position in the sector. When comparing efficiency, CI's gross margin of 8.58% stands against ELV's N/A and HUM's N/A. Such benchmarking helps identify whether The Cigna Group is trading at a premium or discount relative to its financial performance.

Cigna has shown strong revenue growth, with total revenue reaching $71.67 billion in Q2 2026, and a net income of $1.66 billion in the same quarter. However, gross margins have been declining, currently at 8.58%.